Nasdaq

Outlook Therapeutics Discusses NORSE EIGHT Clinical Trial Results and Future Plans for ONS-5010

Outlook Therapeutics, Inc. has announced the participation of Dr. Jennifer Kissner, Senior Vice President of Clinical Development, in a Virtual Investor segment discussing the 12-week safety and ...
Seeking Alpha

Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010

ISELIN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (OTLK) (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the ...
Seeking Alpha

Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD

Positive opinion serves as a basis for final decision for potential authorization from the European Commission (EC), expected within 67 days “The CHMP positive opinion for ONS-5010/LYTENAVA™ ...
Oklahoma's News

Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

ISELIN, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United ...
manilatimes

Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD

ISELIN, N.J., Dec. 31, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of ...
manilatimes

Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

ISELIN, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of ...